Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease

Clinical Biochemistry

Volumn 42, Issue 9, 2009, Pages 802-807

  Yilmaz, Yusuf ^a   Ulukaya, Engin ^b   Gul, Ozen Oz ^b   Arabul, Mahmut ^b   Gul, Cuma Bulent ^b   Atug, Ozlen ^a   Oral, Arzu Yilmaztepe ^b   Aker, Sibel ^b   Dolar, Enver ^b  

^a MARMARA UNIVERSITY   (Turkey)

^b ULUDAG UNIVERSITY   (Turkey)

Author keywords

Biological markers; Enzyme linked immunosorbent assay; Fatty liver; Receptor for advanced glycation endproducts (RAGE)

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALANINE AMINOTRANSFERASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; HUMANS; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC;

EID: 67349263467     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.02.003     Document Type: Article

References (19)

1. Preiss D., and Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin. Sci. (Lond) 115 (2008) 141-150
2. Rector R.S., Thyfault J.P., Wei Y., and Ibdah J.A. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J. Gastroenterol. 14 (2008) 185-192
3. Abdelmalek M.F., and Diehl A.M. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med. Clin. North Am. 91 (2007) 1125-1149
4. Unoki H., and Yamagishi S. Advanced glycation end products and insulin resistance. Curr. Pharm. Des. 14 (2008) 987-989
5. Hyogo H., and Yamagishi S. Advanced glycation end products (AGEs) and their involvement in liver disease. Curr. Pharm. Des. 14 (2008) 969-972
6. Geroldi D., Falcone C., and Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr. Med. Chem. 13 (2006) 1971-1978
7. Hudson B.I., Harja E., Moser B., and Schmidt A.M. Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: the next C-reactive protein?. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 879-882
8. Basta G., Sironi A.M., Lazzerini G., Del Turco S., Buzzigoli E., Casolaro A., et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J. Clin. Endocrinol. Metab. 91 (2006) 4628-4634
9. Geroldi D., Falcone C., Emanuele E., D'Angelo A., Calcagnino M., Buzzi M.P., et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J. Hypertens. 23 (2005) 1725-1729
10. Santilli F., Bucciarelli L., Noto D., Cefalù A.B., Davì V., Ferrante E., et al. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic. Biol. Med. 43 (2007) 1255-1262
11. Butscheid M., Hauptvogel P., Fritz P., Klotz U., and Alscher D.M. Hepatic expression of galectin-3 and receptor for advanced glycation end products in patients with liver disease. J. Clin. Pathol. 60 (2007) 415-418
12. Nomoto K., Tsuneyama K., Abdel Aziz H.O., Takahashi H., Murai Y., Cui Z.G., et al. Disrupted galectin-3 causes non-alcoholic fatty liver disease in male mice. J. Pathol. 210 (2006) 469-477
13. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005) 1313-1321
14. Yan S.F., D'Agati V., Schmidt A.M., and Ramasamy R. Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging. Curr. Mol. Med. 7 (2007) 699-710
15. Devangelio E., Santilli F., Formoso G., Ferroni P., Bucciarelli L., Michetti N., et al. Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic. Biol. Med. 43 (2007) 511-518
16. Nakamura K., Yamagishi S., Adachi H., Kurita-Nakamura Y., Matsui T., Yoshida T., et al. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol. Med. 13 (2007) 185-189
17. Nakamura K., Yamagishi S., Adachi H., Matsui T., Kurita-Nakamura Y., Takeuchi M., et al. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc. Res. 76 (2008) 52-56
18. Nakamura K., Yamagishi S., Adachi H., Matsui T., Kurita-Nakamura Y., Takeuchi M., et al. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. Diabetes/Metab. Res. Rev. 24 (2008) 109-114
19. Hyogo H., Yamagishi S., Iwamoto K., Arihiro K., Takeuchi M., Sato T., et al. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J. Gastroenterol. Hepatol. 22 (2007) 1112-1119